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Abstract Methotrexate (MTX) conjugates with 
poly[Lys(DL-Alam)] based polymeric polypeptides are 
efficient against Leishmania donovani parasite infection, 
but the mechanism of the effect is not known yet. We 
prepared therefore the 5(6)-carboxyfluorescein (Cf) 
labelled oligopeptide [Cf-K(AaAa)]
†
 and the correspoding 
MTX-conjugates [Cf-K(MTX-AaAa)] as model 
compounds for structure-activity experiments. The 
conjugate aimed to be synthesized with solid-phase 
methodology on MBHA resin with Boc strategy, using 
Fmoc-Lys(Boc)-OH. However, various side-reactions were 
identified. Here we report three problems observed during 
the synthesis as well as solutions developed by us: 
a) Unexpected cyclopeptide-formation with the lactone-
carboxylic group of the Cf was detected, when Cf was 
attached to the α-amino group of the Lys residue on solid 
phase. This was avoided by changing the order of Cf 
incorporation with using Fmoc/Dde strategy. Alternatively, 
we have built the peptide with Fmoc strategy on solid 
phase first and performed the labelling with Cf-OSu 
subsequently in solution.  
b) During HF cleavage of the protected conjugates, 
MTX was demonstrated to form adducts with anisole and 
p-cresol scavengers, and the TMSOTf cleavage 
methodology was also found to be inadequate due to the 
large number of side products formed. We report here that 
using Fmoc/Dde strategy is an appropriate method to 
circumvent the cleavage with HF or TMSOTf.  
c) During the coupling of MTX with oligopeptide, 
structural and stereo isomers are formed. We have described 
here the suitable conditions of HPLC separation of these 
products. 
 
† 
Abbreviations: a: D-alanine, A: L-alanine 
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Abbreviations 
 
Boc Tert-butyloxycarbonyl protecting gorup 
BSA Bovine serum albumin 
Cf 5(6)-Carboxyfluorescein 
Cf-OSu 5(6)-Carboxyfluorescein N-hydroxy 
succinimide ester 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM Dichloromethane 
Dde 1-(4,4-Dimethyl-2,6-dioxacyclohexylidene) 
ethyl protecting group 
DEE Diethyl ether 
DIC N,N′-Diisopropylcarbodiimide 
DMF Dimethylformamide  
EDT  1,2-Ethanedithiol 
Fmoc 9-Fluorenylmethoxycarbonyl protecting group 
HF Hydrogen fluoride 
HOBt 1-Hydroxybenzotriazole 
MBHA 4-Methylbenzhydrylamine 
MTX Methotrexate  
TFA Trifluoroacetic acid 
TMSOTf Trimethylsilyl trifluoromethanesulfonate  
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Introduction 
 
Leishmaniasis is one of the most critical tropical 
diseases, as recognized by the World Health Organisation 
(WHO Report, 2000). The treatment has not been fully 
resolved yet. Chemotherapy is available; but the efficiency 
is threatened by the growing incidence of resistant 
parasites, together with the frequent and severe side-effects 
[Sundar, S. et al., 2007] [Das, M. et al., 2013].  
A promising method for destroying the parasites in the 
cells could be the inhibition of the pterine or folate 
metabolism that is different from human metabolism via 
selective inhibition of the pteridine reductase, thymidylate 
synthase or dihydrofolate reductase enzymes 
[Schüttlekopf, A.W. et al., 2005]. Methotrexate (MTX, 
((2S)-2-[[4-[(2,4-diaminopteridin-
6yl)methylmethylamino]benzoyl]amino]pentanedioic acid, 
Fig. 1) could be considered as one of the specific inhibitors 
of dihydrofolate reductase enzyme. It was proven that 
MTX conjugated to bovine serum albumin or maleyl-BSA 
was internalised by macrophages and killed effectively the 
intracellular parasites [Mukhopadhyay, A. et al., 1990].  
 
 
Fig. 1 Methotrexate  
 
Conjugates prepared in our laboratory with efficient 
anti-parasitic effect containing carrier molecules are based 
on poly[Lys(DL-Alam)], (signed as AK
‡
) polymeric 
polypeptide. It contains a poly[L-Lys] backbone (the 
average degree of polymerization = 60-200) and an 
oligo[DL-Ala] side chain (on average 3-4 Ala/Lys) per 
monomeric unit. More, effective derivatives of this family 
of polypeptides with different amino acids in the side chain 
exhibiting different chemical properties (poly[Lys(Xi-DL-
Alam)], XAK
‡
 or poly[Lys(DL-Alam-Xi)], AXK
‡
) were 
described [Hudecz, F. et al., 1993]. 
 
‡Nomenclature of branched chain polypeptides was used in 
accordance with the recommended nomenclature of graft polymers. Short 
codes of the polypeptides are based on one letter abbreviation of amino 
acids. X is a required amino acid in the side chain; m represents the 
average number of amino acids in the side chain; i represents average 
degree of substitution of amino acid X (i1) [IUPAC-IUB, 1984]. 
 
Our aim was to synthesize the appropriate compounds 
corresponding to the monomeric unit of AK and its Cf-
labelled MTX conjugates. Namely, Cf-K(AaAa)-NH2 and 
Cf-K(MTX-AaAa)-NH2 peptide were aimed to perpare for 
structure-activity studies (e.g. chemical stability, 
enzymatic degradation, antiparasitic activity). 
 
 
 
 
 
 
 
 
Fig. 2 The schematic structure of Cf-AK-MTX polymer polypeptide 
conjugate (a) and of the peptide conjugate (b) corresponding to a 
monomeric unit 
 
Here we report on three pitfalls identified during the 
synthesis of the model peptides and conjugates , as well as 
solutions developed by us. 
 
 
Methods 
 
General: The structures of the peptides were verified with 
electrospray ionization mass spectrometry (ESI-MS) and 
UV spectrophotometry. The peptides were purified by 
Reversed Phase High-performance Liquid 
Chromatography (RP-HPLC) (97% <). ESI-MS spectra 
were recorded on Bruker Daltonics Esquire 3000+ ion trap 
mass spectrometer. The reactions were monitored by RP-
HPLC (Phenomenex Synergi C12, 4 µm, 120 Å, 4,6×300 
mm column using  eluent A: 0.1% TFA/H2O, and eluent B: 
0.1% TFA/80% acetonitrile-H2O (V/V), and gradient 
elution 20-80% B (5-20 min) and UV detection: λ=220 
nm). The conjugates were purified by RP-HPLC on 
Phenomenex Jupiter C18, 5µm, 10×300 mm column. 
Gradient elution 5-100% B (5-60 min) for the crude 
product and 10-100% B (5-55 min) for the isolated isomer 
and UV detection (λ=220nm) were applied.  
 
 
Results and discussion 
 
The Cf-K(MTX-AaAa)-NH2 oligopeptide conjugate as 
a model compound (Fig. 2) was synthesized on solid phase 
with conventional peptide synthesis strategy. First, we 
have chosen Boc/MBHA strategy, using Fmoc-Lys(Boc)-
OH as the first coupled amino acid. The side chain of the 
conjugate was built on the -amino group of the protected 
lysine residue with Boc-Ala followed by unprotected 
MTX. For coupling DIC/HOBt assisted activation was 
used. For the removal of the Boc group 33% TFA/DCM 
(V/V), while for the deprotection of the N

-Lys 30% 
piperidine/ 70% DMF (V/V) was utilized. First, the Fmoc-
Lys(Boc)-OH was coupled to the resin, then the Fmoc 
group was cleaved and Cf was attached to the N

-amino 
group of the lysine. It was followed by incorporating the 
alanine side residues also protected by Boc group and then 
the MTX. Finally, the conjugate was cleaved from the 
resin with HF using scavengers (0,5 g p-cresol or 
anisole/10 ml HF).  
During the synthesis we observed serious side-reactions, 
outlined below together with the interpretation and the 
a) 
 
b) 
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a) Acylation with the carboxyl group of Cf 
Unexpected deletion sequences were observed during 
the attachment of Boc-protected alanine residues if Cf was 
present at the -amino-group of the resin attached lysine as 
demonstrated by MS spectra derived from the crude 
product (Fig. 4).  
The likely explanation of the presence of deletion  
sequences could be the tautomeric carboxylic form of the 
fluorescein moiety (Fig. 3) and its reaction with free amino 
group, which resulted in the formation of cyclopeptide 
intermediates.  
 
Fig. 3 Tautomers of 5(6)-carboxyfluorescein 
These cyclic derivatives prevent the incorporation of the 
incoming amino acid and hydrolysed during the HF 
cleavage, thus short peptides with deletion sequences are 
present in the final products (Fig. 4). 
 
a) 
 
 
b) 
 
Fig. 4 Hydrolysis of the cyclic peptides (a) and their ESI-MS 
spectrum (b) 
In the state-of-the-art conjugation practice the lacton bound 
carboxylic group of Cf is expected to be inactive towards 
amide bond formation. By the synthesis of this peptide we 
demonstrate, that under some conditions the reactivity of 
this carboxylic group cannot be neglected. We propose two 
strategies to avoid the formation of these cyclopeptides. 
First, by changing the order of Cf incorporation. Instead of 
the attachment Cf to the Lys(Boc)-Resin, its coupling 
could be performed as the last step of the synthesis after 
the removal of the Fmoc protection of the assembled 
peptide conjugate (Fmoc-K(MTX-AaAa)-Resin). For this 
we have successfully used the Fmoc/Dde strategy (Scheme 
1). Another alternative solution is the solution-phase 
labelling of the free K(MTX-AaAa)-NH2 peptide using Cf-
OSu reagent (Scheme 2). By using  either method we 
completed the synthesis of the aimed product with >97% 
purity (Fig. 5) with acceptable yields (>28%). 
 
Scheme 1 Changing the order of Cf incorporation 
 
 
Scheme 2 Labelling with Cf-OSu in solution 
 
 
a) 
 
b) 
Fig. 5 ESI-MS spectrum (a) and RP-HPLC chromatogram (b) of the 
product 
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b) Failure of Boc strategy for the synthesis 
For labelling the conjugate with Cf-OSu in solution 
(Scheme 2), first we synthesized the K(MTX-AaAa) 
peptide derivative on MBHA resin with Boc strategy. 
During cleavage from the resin with liquid HF we used 
different scavengers. We observed adduct formations with 
the scavenger p-cresol as well as with anisole as evidenced 
by ESI-MS spectrum (Fig. 6).  
 
Fig. 6 ESI-MS spectrum from the p-cresol adduct with K(MTX-
AaAa) M
av
=973,7 
Therefore it was concluded that Boc strategy with HF 
cleavage seems to be inadequate for the synthesis of MTX 
containing peptide conjugates, because the sensibility of 
the MTX aromatic moiety on carbocation attack.  
Based on the ESI-MS spectrum of the isolated product we 
have postulated the structure one of the possible adducts 
(Fig. 7). Further studies are needed to clarify the exact 
position of substitution. 
 
Fig. 7 A hypothesized side-product with anisole  
 
In order to avoid the adduct formation we have tried 
TMSOTf based cleavage without success. We observed the 
formation of a complex mixture with more than 10 
components and the target compound was not identifiable 
with RP-HPLC analysis (data not shown). 
In order to avoid the harsh cleavage conditions that are not 
compatible with MTX we utilised Fmoc/Dde strategy on 
MBHA resin with Rink-amide spacer (Scheme 1). The 
mild cleavage circumstances (95% TFA/ 2,5% water/ 2,5% 
TIS (V/V/V)) does not cause side-reactions, thus the aimed 
peptide was possible to be synthesized with high purity 
(>97%) and yield (>28%).  
c) Formation of MTX isomers  
The RP-HPLC analysis of MTX-containing conjugates 
(MTX-AaAa, K(MTX-AaAa), Cf-K(MTX-AaAa)) showed 
three peaks of approx. equal intensity implying of isomer 
formation around the glutamic acid moiety of MTX. 
The formation of such MTX isomers were studied earlier [V 
Subr et al., 1997]. The presence of the α and γ MTX isomers 
in approximately equal quantities is not surprising, thus the 
α and γ carboxylic groups of MTX have about the same 
reactivity under the used DIC/HOBt acylation system (Fig. 
8). Furthermore, the lack of an urethane type protecting 
group at the α amino group of the MTX could result in 
racemisation around the alpha carbon, when coupling is 
done on the α carboxyl. 
 
 
Fig. 8 Formation sites of MTX-peptide isomers 
 
 
Fig. 9 RP-HPLC chromatogram of the crude MTX-AaAa peptide 
conjugate product (gradient elution 5-100% B (5-60 min) and UV 
detection (λ=220nm) were applied) and one of the purified isomers 
(insert, gradient elution 10-100% B (5-55 min). 
 
We observed that changing the coupling conditions does 
not alter the isomeric composition significantly, thus the 
most practical way to obtain the isomerically pure MTX-
peptide conjugate was to separate the isomers by HPLC.  
All three MTX peptide isomers (α L/D and γ L) isolated 
after semi-preparative RP-HPLC separation (Fig. 9) were 
characterized by ESI-MS. Co-injection experiments 
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together with molecular mass values support the presence 
of all isomers.
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Discussion 
 
In our study presented here we identified the following 
possible side reactions that may interfere with the 
successful synthesis of MTX-oligopeptide conjugates: 
a) the generally inert lacton-bound carboxylic group of 
Cf is proved to be responsible for acylation side-
reactions in the presence of DIC/HOBt activation. In 
orer to circumvent this problem the coupling of Cf 
should be the last step of conjugate synthesis. 
b) MTX is proved to be sensitive for HF/TMSOTf 
cleavage conditions, thus these conditions should be 
avoided. 
c) the formation of three MTX isomers in about equal 
amounts are demonstrated. The isomerically pure 
model peptides obtained by HPLC can be useful to 
clarify the significance of this side reaction in the 
pharmacological behavior of the product. The 
formation of such isomer conjugates are known from 
previous studies [A Nagy et al., 1993] in the case of 
peptide hormones. 
The results presented here can be utilized predominantly to 
study comparatively the biological properties (e.g. the 
effect on cell proliferation, cytotoxicity) of the peptides 
and the peptide-conjugates (Table 1). We wish to 
understand the fate of the active MTX-branched 
polypeptide conjugates reported earlier [Gy Kóczán et al., 
2002] in the cell. Therefore we aim to utilize the MTX-
oligopeptide conjugates as monomeric unit and follow its 
uptake as well as intracellular traffic and degradation. 
These experiments will be accomplished by e.g. 
fluorescent microscopy examinations, flow-cytometry 
measurements and cell proliferation test Furtherrmore, the 
observations described could help to improve the synthesis 
of MTX-polymeric polypeptide conjugates with 
fluorophore labels.  
  
 
Table 1 The synthesis strategy used and the chemical characteristics of peptides and conjugates 
Compounds 
 
Strategy Rt  
(min) 
Mav 
calc/meas  
ESI [M+H]
+ 
Boc Fmoc Dde/ 
Fmoc 
AaAa-NH2 n.t. + n.t. 10.4 301.33/302.3 
MTX-AaAa-NH2 - + n.t. 22.1/22.2/22.3 737.77/738.3 
K(aAaA)-NH2 + + n.t. 11.5 429.50/430.4 
K(MTX-aAaA)-NH2 - + n.t. 24.6/25.0/25.3 865.97/866.5 
Cf-K(aAaA)-NH2 + + n.t. 25.4 787.82/788.6 
Cf-K(MTX-aAaA)-NH2 - - + 27.2/27.3/27.5 1224.26/1224.4 
 
+: successful synthesis 
-: unsuccessful synthesis 
n.t.: not tested 
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General protocol of Boc strategy: For the synthesis MBHA resin 
was used (capacity 1,12 mmol/g). The resin was swelled in DCM 
for 3×10 minutes and treated with 33% TFA/DCM (V/V) solution 
for 2+20 minutes, then washed with DCM 5×, as neutralization 
with 10% DIEA/DCM (V/V) solution 4× and again with DCM 4×. 
After that the peptide was built on the resin. For the amino acid and 
MTX coupling DIC/HOBt coupling agents were used (amino acid : 
DIC : HOBt = 3,5eq : 3eq : 3eq) in DMF. The reaction time of 
coupling was 60 minutes. After each coupling a wash with DMF 
6× and DCM 6× was done. For controlling the success of the 
coupling ninhydrin-test was used. Based on this method all 
couplings were successful (˃99.5% conversion). Cleaving of the 
Boc group was performed by 33% TFA/DCM (V/V) solution for 
2+20 minutes. After the cleavage the resin was washed with DCM 
5×, as neutralization with 10% DIEA/DCM (V/V) solution 4× and 
again with DCM 4×. The Fmoc protecting group was removed with 
2% piperidine + 2% DBU/DMF (V/V) solution for 2+2+5+10 
minutes, then  a wash with DMF 6× and then with DCM 6× was 
applied. Before cleavage the peptide from the resin it was washed 
with MeOH and DEE, and the resin with the peptide was dried 
during a night in desiccator. 
  
Cleavage the peptide from the resin with HF was done in a suitable 
teflon equipment for 120 minutes, in the presence of p-cresol or 
anisole scavengers (0,5 g scavenger/10 ml HF was used). Then the 
peptide was precipitated by 50 ml cooled DEE, filtered, and 
washed 3× with DEE on the filter. The peptide was dissolved in 
10% acetic acid solution, separated from the resin with filtration. 
The solution was lyophilised to isolate the product.  
 
For the TMSOTf cleavage a mixture of TMSOTf/tioanisole/EDT/ 
p-cresol/TFA (1/0,5/0,25/0,25/3 (V/V/V/V/V)) solution was used 
for 120 minutes at RT. After the cleavge 50-60 ml cooled DEE was 
added and the mixture was centrifuged. The peptide was dissolved 
in 10% acetic acid solution and it was lyophilised to isolate the 
product.  
 
The general protocol for Fmoc strategy: For the synthesis MBHA 
resin with Rink-Amide linker was used (capacity 0,56 mmol/g). 
The resin was swelled in DCM for 2×10 minutes. Then the Fmoc 
protecting group of the resin was cleaved by 2% piperidine + 2% 
DBU/DMF (V/V) solution for 2+2+5+10 minutes, then the resin 
was washed with DMF 6× and DCM 6×. After that the peptide was 
built on the resin. For the amino acid and MTX coupling 
DIC/HOBt coupling agents were used (amino acid : DIC : HOBt = 
3,5eq : 3eq : 3eq) in DMF. The reaction time of coupling was 60 
minutes. After each coupling a wash with DMF 6× and DCM 6× 
was done. For controlling the success of the coupling ninhydrin-test 
was used. The cleavage of the Fmoc protecting group of the amino 
acids was done with the same method as in the case of the cleavage 
of the resin’s Fmoc group. Before cleavage the peptide from the 
resin it was washed with MeOH and DEE, and the resin with the 
peptide was dried during a night in desiccator. 
 
For the cleavage the peptide from the resin TFA/H2O/TIS solution 
(0,95/0,025/0,025 (V/V/V)) was used for 120 minutes at RT. Then 
the mixture was filtered into 50-60 ml cooled DEE. The solution 
mixture was removed by evaporation. The peptide was dissolved in 
10% acetic acid solution and lyophilised to isolate the product. 
 
Synthesis of Cf-K(MTX-AaAa)-NH2 peptide conjugate:  
In solution: The K(MTX-aAaA)-NH2 peptide conjugate was 
synthesized on Rink-Amide MBHA resin with Fmoc strategy. For 
the synthesis Boc-Lys(Fmoc)-OH, Fmoc-D-Ala-OH, Fmoc-L-Ala-
OH and MTX was used. First the Boc-Lys(Fmoc) was coupled to 
the resin, than the side chain was built on the ε amino group of the 
lysine. The remove of Boc group and the cleavage from the resin 
was done by TFA in the presence of H2O and TIS. Then the 
purified K(MTX-AaAa)-NH2 peptide conjugate was dissolved in 
DMF and Cf-OSu was coupled in the presence of DIEA basis 
(peptide : Cf-OSu : DIEA = 1eq : 1,5eq : 1eq). The peptide was 
purified by RP-HPLC. 
 
On solid phase: The synthesis was done on Rink-Amide MBHA resin 
with Fmoc/Dde strategy. For the synthesis Dde-Lys(Fmoc)-OH, 
Fmoc-D-Ala-OH, Fmoc-L-Ala-OH, MTX and Cf was used. First 
the Dde-Lys(Fmoc)-OH was coupled to the resin, then the side 
chain was built on the ε amino group of the lysine, and finally the 
Dde group was cleavaged and the Cf was coupled. The Dde 
protecting group was removed by 2% H2N-NH2.H2O/DMF (V/V) 
solution for 6×5 minutes, then wash with DMF 6× and DCM 6× 
was applied.  The peptide was purified by RP-HPLC. 
 
 
 
